QQ客服 官方微博 反馈留言

	E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments
	Lan, Wenjun[1,2,3]; Bian, Benjamin[1,2]; Xia, Yi[4]; Dou, Samir[1,2]; Gayet, Odile[1,2]; Bigonnet, Martin[1,2]; Santofimia-Castano, Patricia[1,2]; Cong, Mei[3]; Peng, Ling[3]; Dusetti, Nelson[1,2]
	2018
卷号	8
URL标识	查看原文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3193479
专题	重庆大学
推荐引用方式 GB/T 7714	Lan, Wenjun[1,2,3],Bian, Benjamin[1,2],Xia, Yi[4],et al. E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments[J],2018,8.
APA	Lan, Wenjun[1,2,3].,Bian, Benjamin[1,2].,Xia, Yi[4].,Dou, Samir[1,2].,Gayet, Odile[1,2].,...&Iovanna, Juan[1,2].(2018).E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments.,8.
MLA	Lan, Wenjun[1,2,3],et al."E2F signature is predictive for the pancreatic adenocarcinoma clinical outcome and sensitivity to E2F inhibitors, but not for the response to cytotoxic-based treatments".8(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。